IMBiologics Corp. (KOSDAQ:493280)

Market Cap	752.10B
Revenue	n/a
Net Income	n/a
EPS	n/a
Shares Out	14.78M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	123,824
Average Volume	162,630
Open	53,600
Previous Close	53,700
Day's Range	50,300 - 54,400
52-Week Range	26,000 - 104,000
Beta	n/a
RSI	50.78
Earnings Date	n/a

About IMBiologics

IMBiologics Corp., a biotechnology company, engages in developing immunomodulatory antibody therapeutics to treat autoimmune diseases and cancer. The company uses Optimal Antibody Modality Manufacturing Technology (IM-OpDECon) for developing differentiated treatments for autoimmune diseases and immuno-oncology based on immuno-modulatory biologics. Its products include IMB-101, a bispecific therapeutic antibody that targets OX40L and TNF to modulate pathological immune mechanisms mediating Th1/Th17 immune responses; IMB-102; IMB-201, an antibody...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2020
• Country: South Korea
• Stock Exchange: KOSDAQ
• Ticker Symbol: 493280